Immunomodulatory effect of immunoglobulins

Area of Science:

• Immunology
• Rheumatology
• Neurology

Background:

• Intravenous immunoglobulin (IVIG) is a primary treatment for various autoimmune and inflammatory conditions, including Kawasaki disease, immune thrombocytopenia (ITP), and Guillain-Barré syndrome.
• Extensive clinical trials support its use, establishing it as a treatment of choice.

Purpose of the Study:

• To review the established clinical indications for IVIG.
• To explore the known in vitro and in vivo mechanisms of action for IgG in modulating immune and inflammatory responses.
• To highlight the ongoing need for research to correlate specific mechanisms with clinical efficacy in distinct diseases.

Main Methods:

• Review of large clinical trials demonstrating IVIG efficacy.
• Analysis of in vitro and experimental animal studies identifying cellular and molecular mechanisms of IgG action.
• Discussion of theoretical mechanisms, such as idiotype network interference.

Main Results:

• IVIG is clinically effective in numerous inflammatory and autoimmune diseases.
• Identified mechanisms include Fc-receptor blockade and down-modulation, acting as a sink for complement components.
• Other proposed mechanisms involve interference with the idiotype network and modulation of cytokine profiles, including increased IL-1 receptor antagonist.

Conclusions:

• IVIG is a well-established therapy for specific autoimmune and inflammatory diseases.
• Multiple mechanisms of action have been proposed and demonstrated in basic research.
• Further investigation is required to precisely link these mechanisms to IVIG's clinical effectiveness in individual diseases.